Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Friday 12 July, 2019

Winchester MD Ltd

Winchester MD Leads Sponsorship of IC3 London

RNS Number : 3054F
Winchester MD Limited
12 July 2019
 

 

Winchester MD Leads Sponsorship of IC3 London

 

LONDON, 12th July 2019 - WINCHESTER MD LIMITED ("Winchester" or the "Company") is pleased to announce that it was lead sponsor and an exhibitor at the Inaugural Institutional Capital & Cannabis Conference (Europe) in London.

 

IC3 forums are a meeting place for investors who wish to learn more about cannabis companies and investment funds who are looking to raise money or showcase their products, and professional service providers who facilitate these groups doing business.

 

IC3 conferences have earned a reputation in the US for quality content, expert speakers, and a high representation of institutional investors among its delegates. Winchester's co-founder, Dan Kriznic, and its legal counsel, Fraser McGee both sat on industry expert panels and CEO, Faz Moshfeghi, was interviewed on stage in a strategic session led by Tristan Gervais, the London leader of Canaccord Genuity's Cannabis sector team.

 

Faz Moshfeghi, CEO of Winchester MD commented: "We are delighted both with the new contacts we made at IC3 and with the positive feedback from investors and industry stakeholders on our exciting expansion strategy to build on our profitable UK on-line cannabis superstore".

 

For more information, please visit www.winchestermd.com

 

On Behalf of the Board,

Faz Moshfeghi

CEO

[email protected]

 

About Winchester MD Limited

Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail superstore platform HempElf www.hempelf.com. The Company offers a variety of CBD branded products through its on line superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development. 

 

This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.

 

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

 

The Regulation Services Provider accepts no responsibility for the adequacy or accuracy of this release.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRACKDDQOBKDQOD

a d v e r t i s e m e n t